GlassScriptPhysician profile
Kurt R Bravata
NPI 1790096170
$8,321.54
in general payments reported to CMS, 2019-2025
50 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $796 · 2021: $1,821 · 2022: $1,386 · 2023: $1,175 · 2024: $1,134 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,499 · Education: $52.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,498.79 |
| Education | $52.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $882.73 | 2021-2025 | Vraylar, Mavyret, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $822.54 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $729.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $712.12 | 2019-2025 | |
| Lilly USA, LLC | $608.90 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $432.17 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Glaxosmithkline, LLC. | $365.00 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $338.17 | 2019-2025 | Trintellix |
| Amgen INC. | $298.94 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.29 | 2019-2023 | Jardiance |
| Alkermes, INC. | $203.80 | 2019-2023 | Vivitrol |
| Biohaven Pharmaceutical Holding Company LTD. | $203.13 | 2022 | |
| Braeburn INC. | $201.88 | 2023-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $188.13 | 2019-2025 | Rexulti |
| Astellas Pharma US INC | $166.65 | 2019-2025 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Bravata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.